Literature DB >> 16606956

Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

Rajesh Hiralal1, Karen K Y Koo, Hertzel C Gerstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16606956      PMCID： PMC1421458          DOI： 10.1503/cmaj.060049

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

Authors:  A J Karter; A T Ahmed; J Liu; H H Moffet; M M Parker
Journal:  Diabet Med       Date:  2005-08       Impact factor: 4.359

2.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Authors:  Thomas E Delea; John S Edelsberg; May Hagiwara; Gerry Oster; Lawrence S Phillips
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

3.  A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

Authors:  Matthias Herz; Don Johns; Jesus Reviriego; Loren D Grossman; Chantal Godin; Santiago Duran; Federico Hawkins; Heather Lochnan; Fernando Escobar-Jiménez; Philip A Hardin; Christopher S Konkoy; Meng H Tan
Journal:  Clin Ther       Date:  2003-04       Impact factor: 3.393
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.